Sign in

You're signed outSign in or to get full access.

Sharyn Leaver

Chief Research Officer at FORRESTER RESEARCH
Executive

About Sharyn Leaver

Sharyn Leaver is Chief Research Officer at Forrester (FORR), age 50, serving in this role since January 2022; she joined Forrester in 2001 and previously led research organizations within the firm . Company performance drivers tied to executive pay emphasize CV bookings growth and modified operating income, with 2024 results showing revenues down 10.0% to $432.5 million; the company nevertheless met final revenue, adjusted operating margin, and adjusted EPS guidance, while executive cash incentives were suspended and replaced with discretionary bonuses . Pay-versus-performance disclosure highlights that 2024 company TSR translated to $38 from a fixed $100 investment, net income was -$5.7 million, and year-over-year CV bookings growth was -5.3%, underscoring the firm’s use of equity incentives and CV-linked metrics in compensation .

Past Roles

OrganizationRoleYearsStrategic Impact
Forrester Research, Inc.Chief Research OfficerJan 2022–present Not disclosed
Forrester Research, Inc.Senior Vice President, ResearchNov 2018–Jan 2022 Not disclosed
Forrester Research, Inc.Vice President and Group Research DirectorOct 2013–Nov 2018 Not disclosed
Forrester Research, Inc.Joined Forrester2001–present Not disclosed

External Roles

No external public-company directorships or committee roles are disclosed in Forrester’s filings for Leaver .

Fixed Compensation

Multi-year compensation structure for Sharyn Leaver (named executive officer) as reported:

MetricFY 2022FY 2023FY 2024
Base Salary ($)374,556 375,600 375,600
Target Bonus ($)Not disclosed225,000 Not applicable (plan suspended)
Actual Bonus Paid ($)90,000 60,750
Non-Equity Incentive Plan ($)123,750 — (plan suspended; amounts were discretionary)
Stock Awards ($)324,981 485,449 349,986
Option Awards ($)323,191
All Other Compensation ($)10,400 8,742 14,032
Total ($)833,687 1,282,982 800,368

2024 bonuses were discretionary due to suspension of the Executive Cash Incentive Plan .

Performance Compensation

Long-term equity awards and vesting (grants and schedules)

Grant DateAward TypeShares/Options Granted (#)Fair Value ($)Vesting Terms
04/01/2024Time-based RSUs16,802 349,986 25% annually on 4/1/2025, 4/1/2026, 4/1/2027, 4/1/2028
03/01/2023Stock Options22,699 323,191 25% annually on 3/1/2024, 3/1/2025, 3/1/2026, 3/1/2027; strike $33.04
03/01/2023Time-based RSUs9,836 324,981 25% annually on 3/1/2024, 3/1/2025, 3/1/2026, 3/1/2027
03/01/2023Performance RSUs (PSUs)Threshold 730; Target 3,246; Max 4,869 107,248 Vests on or after 3/1/2026 based on CV growth and Adjusted EBITDA margin
04/03/2023Performance RSUs (PSUs)Threshold 376; Target 1,672; Max 2,508 53,220 Same PSU metrics; measurement year 2025

The Compensation Committee did not issue PSUs in 2024 given 2023 performance and projected 2024 results; 2024 RSUs vest over four years .

PSU performance metrics and payout scales (Measurement Year: FY2025)

MetricWeightingThresholdTargetMaximumPayout Scale
CV Growth PSUs75% of PSU grant 90% of CV Growth Target → 30% payout 100% of CV Growth Target → 100% payout 105% of CV Growth Target → 150% payout Linear interpolation between levels
Adjusted EBITDA Margin PSUs25% of PSU grant 1% point below margin target → 30% payout Margin target → 100% payout 1% point above margin target → 150% payout Linear interpolation between levels

PSUs can vest between 22.5% and 150% of grant depending on performance; vesting on 3/1/2026 if thresholds met .

2024 realized vesting

Metric2024
RSUs vested (#)5,593
Value realized on vesting ($)112,015
Options exercised (#)
Value realized on option exercise ($)

Equity Ownership & Alignment

Beneficial ownership snapshot

As-of DateShares Beneficially Owned (#)Shares Subject to Exercisable Options/Vesting RSUs within 60 days (#)% of Outstanding
03/18/202411,258 5,675 <1%
03/17/202515,024 15,550 <1%

Stock ownership guidelines and policies

  • Executives must hold at least 1× total annual on-target earnings in Forrester stock; five-year compliance window; targets set using the 200-day moving average as of 4/1/2024; restrictions on sales apply until guidelines are met; unexercised options and unvested RSUs do not count; all executives are in compliance since adoption .
  • Insider Trading Policy filed with 2024 10-K; company currently has no hedging policy; no pledging policy disclosure noted .
  • Outstanding awards at 12/31/2024 indicate options strike $33.04 vs. $15.67 stock price, leaving options out-of-the-money at year-end .

Outstanding equity awards and schedules (as of 12/31/2024)

Award TypeCount (#)Vesting DatesNotes
Time-based RSUs826 Vests 8/1/2025
Time-based RSUs3,228 50% on 3/1/2025; 50% on 3/1/2026
Time-based RSUs7,377 1/3 each on 3/1/2025, 3/1/2026, 3/1/2027
Time-based RSUs16,802 25% each on 4/1/2025, 4/1/2026, 4/1/2027, 4/1/2028 2024 grant
Performance RSUs4,918 (at target) Can vest 3/1/2026 (22.5%–150% based on performance) CV and Adjusted EBITDA metrics
Stock Options5,675 exercisable; 17,024 unexercisable Footnote indicates tranches begin 3/1/2025–3/1/2027 Strike $33.04; expires 2/28/2033

Employment Terms

Executive Severance Plan highlights

  • Without cause (no change-in-control): 12 months of base salary continuation, lump-sum bonus based on lesser of target vs two-year average, 12 months of company medical/dental contributions, and 6 months of outplacement (extendable) .
  • With change-in-control and qualifying termination (double trigger within 18 months): lump-sum base salary (1× for executives), lump-sum incentive adjustments, higher of target vs two-year average bonus, 12 months of medical/dental contributions, 12 months of outplacement, acceleration/cash-out of unvested equity at target for performance awards; reimbursement of legal fees if prevailing .
  • No 280G tax gross-up; cutback to avoid excise tax where applicable; award agreements provide for single-trigger full acceleration upon change in control unless awards are assumed/substituted/cashed-out .

Estimated payments for Leaver (as of 12/31/2024)

ScenarioSalary Continuation / Lump Sum ($)Incentive Compensation ($)Medical & Dental ($)Outplacement ($)Accelerated Unvested Equity ($)Total ($)
Change in control (no termination)519,476 519,476
Termination without cause (no change-in-control)375,000 106,875 25,402 10,000 517,277
Termination upon change-in-control (double trigger)375,000 389,250 25,402 20,000 519,476 1,329,128

Compensation Structure Notes and Governance

  • Pay mix: base salary, short-term cash incentive, and long-term equity (RSUs and, periodically, options); severance/change-of-control benefits and broad-based benefits .
  • 2024 executive cash incentive plan suspended; discretionary bonuses approved instead .
  • Committee members: Robert M. Galford (Chair), Robert Bennett, David Boyce, Yvonne Wassenaar; Committee validated CD&A and emphasized flexibility to link a significant portion of compensation to performance .
  • Non-binding say-on-pay proposal recommended FOR by the Board .
  • Clawback policy aligned to SEC/NASDAQ rules; mandatory recovery of erroneously awarded incentive comp for three fiscal years preceding a restatement date; effective for compensation received on/after 10/2/2023 .

Investment Implications

  • Alignment and retention: Stock ownership guidelines (1× on-target earnings) and compliance enhance alignment; large scheduled RSU vestings in 2025–2026, plus options tranches, suggest periodic supply from net-share settlements, though options were out-of-the-money at $15.67 vs. $33.04 strike at 12/31/2024, reducing near-term exercise pressure .
  • Pay-for-performance design: Incentives emphasize CV bookings and adjusted profitability via PSUs; no 2024 PSU issuance underscores a conservative stance given 2023/2024 trajectories; 2024 discretionary bonuses reflect discipline amid revenue decline (-10%) and TSR pressure .
  • Change-of-control economics: Double-trigger severance totals of ~$1.33 million and single-trigger equity acceleration at ~$0.52 million indicate moderate personal economics in M&A scenarios, potentially neutral to management continuity incentives .
  • Governance signals: Absence of an anti-hedging policy is a relative red flag versus best practice; no pledging policy disclosure; robust clawback implementation mitigates restatement risk concerns .